Mergers & Acquisitions Mergers & Acquisitions

Race between Grail, rivals will be harmed by Illumina deal, US FTC tells court

By Jenna Ebersole and Austin Peay
  • 24 Aug 2021 17:32
  • 21 Oct 2021 05:27
Grail and its rivals are in a race on early-detection cancer screening tests even though Grail has the only product on the market so far, and the Illumina-Grail deal threatens innovation in the life-saving technology, a US Federal Trade Commission lawyer said today.
“The gun has gone off and the

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Discover MLex

Stay on top of global regulatory developments

Latest News